Reach FDA 21 CFR Part 312 — IND Applications readiness without rebuilding your policy programme
FDA 21 CFR Part 312 governs Investigational New Drug (IND) applications — required before a drug can be shipped across state lines for clinical investigation. Covers commercial vs treatment vs investigator-sponsored INDs, content + format (Form FDA 1571), safety reporting (IND Safety Reports per §312.32 / 7- or 15-day timelines), clinical hold authorities, sponsor obligations + investigator obligations. Failure to comply has resulted in clinical holds + sponsor + investigator disqualification. Quick Policy maps FDA 21 CFR Part 312 — IND Applications into the policy families, controls, and evidence your team needs - and keeps it current between audits.
Standards assurance
How Quick Policy verifies against FDA 21 CFR Part 312 — IND Applications
Every policy Quick Policy generates is scored against FDA 21 CFR Part 312 — IND Applications's pass mark, with a PASS, WARN, or FAIL verdict and plain-English guidance on what to fix when it falls short.
A monthly automated audit re-checks coverage against this standard, so drift is caught between scheduled reviews rather than at the next one.
Audit-ready exports bundle the scored policies, gap guidance, and review history into one evidence pack when it is time to show your work.
FDA 21 CFR Part 312 — IND Applications quick answer
Standard facts
Framework: FDA_IND
Authority: US Food and Drug Administration (FDA / CDER + CBER)
Jurisdiction: US
Why FDA 21 CFR Part 312 — IND Applications matters for your operating model
FDA 21 CFR Part 312 — IND Applications doesn't just dictate document templates - it shapes which controls auditors test, what evidence they ask for, and which gaps surface first during diligence. Getting it wrong creates renewal slippage, audit findings, and stalled customer deals.
- • Issued by US Food and Drug Administration (FDA / CDER + CBER) and primarily enforced in US.
- • Directly shapes policy families including Clinical Trials, Pharmacovigilance — these are the artefacts assessors open first.
- • Common artifacts include Policy.
- • Obligation model: Mandatory In Scope — meaning you need defensible reasoning for in-scope vs out-of-scope decisions, not just signed policies.
How Quick Policy helps you stand up FDA 21 CFR Part 312 — IND Applications
The platform turns FDA 21 CFR Part 312 — IND Applications from a PDF of requirements into a live operating model - policies, training, evidence, and audit-export packs that update in lock-step when the standard or your business changes.
- • Adopt FDA 21 CFR Part 312 — IND Applications once and Quick Policy seeds the right policy families (Clinical Trials, Pharmacovigilance) with applicability rationale your auditor can follow.
- • Common artifacts include Policy.
- • Review cadence is enforced at ~365 days so policies don't silently expire ahead of recertification.
- • Standard updates (FDA 21 CFR Part 312 — IND Applications revisions, errata, regulator guidance) trigger an applicability re-check across your active policies - not a full rewrite.
Policy families commonly involved
Recommended artifacts and context
Industry tags: LIFE_SCIENCES
Obligation model: Mandatory In Scope
Coverage depth: Profile
How Quick Policy puts FDA 21 CFR Part 312 — IND Applications into practice
Turn standards context into drafting, review, training, and evidence workflows that are easier to maintain over time.
Capture Core Profile
Admins complete adaptive onboarding to establish operating model, risk posture, and compliance objectives.
Determine Applicable Standards
Standards applicability ranks obligations by industry, geography, services, and data profile.
Generate and Harmonise Policy
Three-pass generation drafts, repairs contradictions, and validates coverage before reviewer handoff.
Review, Approve, and Sign Off
Approvers validate policy language, mappings, and obligations, then publish through a sign-off chain that tracks every person against every policy on one exportable compliance matrix.
Need adjacent guidance?
Use these pages for broader platform, industry, or buying context around FDA 21 CFR Part 312 — IND Applications.
Get FDA 21 CFR Part 312 — IND Applications-ready without the consultant invoice
Start a guided preview - no card, no sales call. See how FDA 21 CFR Part 312 — IND Applications applies to you and draft your first aligned policy preview before you pick a plan; publishing and audit-ready exports unlock after checkout.
FDA 21 CFR Part 312 — IND Applications FAQs
What does FDA 21 CFR Part 312 — IND Applications actually require?
FDA 21 CFR Part 312 governs Investigational New Drug (IND) applications — required before a drug can be shipped across state lines for clinical investigation. Covers commercial vs treatment vs investigator-sponsored INDs, content + format (Form FDA 1571), safety reporting (IND Safety Reports per §312.32 / 7- or 15-day timelines), clinical hold authorities, sponsor obligations + investigator obligations. Failure to comply has resulted in clinical holds + sponsor + investigator disqualification. In practice that means the policies, controls, and evidence around Clinical Trials, Pharmacovigilance need to be authored, owned, tested, and producible on demand. Quick Policy maps each requirement to a policy section and evidence type so you can show coverage clause-by-clause.
How does Quick Policy accelerate FDA 21 CFR Part 312 — IND Applications adoption?
When you adopt FDA 21 CFR Part 312 — IND Applications, Quick Policy auto-recommends the policy families, applicability decisions, and evidence types that align to it. Drafting uses FDA 21 CFR Part 312 — IND Applications-aware AI prompts so drafts arrive pre-mapped to clauses - not as blank templates you have to wire up afterwards.
Will adopting FDA 21 CFR Part 312 — IND Applications in Quick Policy replace our auditor or assessor?
No - Quick Policy gets you to a defensible operating programme that an assessor or auditor can review against FDA 21 CFR Part 312 — IND Applications. We provide the policy artefacts, evidence trails, and exports they need; certification, attestation, or audit opinion remains the assessor's role.
What if FDA 21 CFR Part 312 — IND Applications is updated mid-cycle?
Standard revisions, errata, and regulator guidance feed back into the applicability engine. You get a watchdog alert with the affected policies, recommended next actions, and a one-click re-baseline against the new version — without scrapping the work already in place.